Relapse and Remission of Paraneoplastic Neurologic Syndromes:One Case Report and Literature Review

Paraneoplastic neurologic syndromes (PNS) is a group of heterogeneous diseases that occurs in tumor patients and can affect the central nervous, peripheral nerve, neuromuscular junction and muscle. The diagnosis should exclude tumor metastasis, infection, metabolic and nutritional defects and side effects of tumor treatment. The cause of PNS is believed to be related to immune factors, such as anti-nervous system antigen antibodies and T-cell immune response. PNS can appear 5 years before the tumor appears, which has an important role in suggesting the occurrence of tumor. We report a PNS case which imaging improves but symptoms become volatile.

[1]  J. Dalmau,et al.  Antibody-associated CNS syndromes without signs of inflammation in the elderly , 2017, Neurology.

[2]  C. Chapman,et al.  Paraneoplastic neurologic disorders in small cell lung carcinoma , 2015, Neurology.

[3]  W. Mason,et al.  Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies , 2014, The Lancet Neurology.

[4]  P. Fallon,et al.  Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[5]  F. Ducray,et al.  Delayed onset of a second paraneoplastic neurological syndrome in eight patients , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[6]  J. Honnorat,et al.  Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. , 2010, Archives of neurology.

[7]  V. Lowe,et al.  Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. , 2008, Mayo Clinic proceedings.

[8]  A. Twijnstra,et al.  P/Q-type calcium channel antibodies, Lambert–Eaton myasthenic syndrome and survival in small cell lung cancer , 2005, Journal of Neuroimmunology.

[9]  M. Rosenfeld,et al.  Clinical analysis of anti-Ma2-associated encephalitis. , 2004, Brain : a journal of neurology.

[10]  J. Honnorat,et al.  Recommended diagnostic criteria for paraneoplastic neurological syndromes , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  J. Rees,et al.  Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  G. Escaramís,et al.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. , 2001, Brain : a journal of neurology.

[13]  J. Honnorat,et al.  Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone , 2000, Journal of neurology, neurosurgery, and psychiatry.

[14]  W. Mason,et al.  Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. , 1997, Brain : a journal of neurology.

[15]  R. Darnell.  Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. O'fallon,et al.  Immunomodulatory treatment trial for paraneoplastic neurological disorders. , 2004, Neuro-oncology.

[17]  M. Rosenfeld,et al.  Current therapies for paraneoplastic neurologic syndromes , 2003, Current treatment options in neurology.